THOC5 is a member of the THO complex that is involved in processing and transport of mRNA. We have shown previously that hematopoietic stem cells have an absolute requirement for THOC5 for survival and that THOC5 is phosphorylated on tyrosine 225 as a consequence of leukemogenic protein tyrosine kinase (PTK) action. We have investigated pathways for THOC5 phosphorylation to develop an understanding of THO complex modulation by tyrosine kinase (TK) oncogenes in leukemias. We demonstrate that THOC5 phosphorylation is mediated by Src PTK and CD45 protein tyrosine phosphatase action and that this event is sensitive to oxidative status. We show that THOC5 phosphorylation is elevated in stem cells from patients with chronic myeloid leukemia (CML) and that this phosphorylation is sensitive to the frontline drugs used in CML treatment. Further we show that THOC5 Y225 phosphorylation governs mRNA binding. In addition, CXCL12 is shown to induce THOC5 Y225 phosphorylation, and site-directed mutagenesis demonstrates that this modulates motile response. In conclusion, we delineate a signaling pathway stimulated by leukemogenic PTKs, chemokines and oxidative stress that can affect THO complex mediation of gene expression describing mechanisms for post-transcriptional regulation of protein levels.
INTRODUCTION
THOC5/Fms-interacting protein is a member of the THO complex, which in turn is a part of the TREX (transcription/export) complex. TREX has been conserved from yeast to man and has been shown to be required for coupled transcription elongation and nuclear export of mRNAs. 1 In Drosophila melanogaster, decreases in the THO complex reduce overall protein synthesis by approximately half, although there is an increase in specific proteins, including those involved in DNA repair. 2 In yeast, a similar effect is observed, suggesting a relationship between the THO complex and response to adverse changes in the cellular environment. 3 The THO complex is associated with the messenger ribonucleoparticle, the nascent RNA and the (nuclear) exported RNA. Mutations in the THO complex can lead to decreased polyadenylation of RNAs and their enhanced rate of degradation. Heat-shock protein 70 is one gene product that can be regulated by THO complex; specifically, THOC5 binds heat-shock protein 70 messenger ribonucleoparticle and associates with the Tap-p15 bulk mRNA nuclear export receptor to facilitate export. 4, 5 THOC5 has been implicated in the regulation of differentiation and development via modulation of transcription factor C/EBPa, 6 a gene often mutated in human leukemias. This protein regulates adipocyte and neutrophil/ macrophage development. 6 Indeed, THOC5 was originally named Fms-interacting protein and identified as a substrate and binding partner of the macrophage-colony-stimulating factor receptor. 7 THOC5 is a 75 kDa phosphoprotein found both in the nucleus and cytoplasm and is phosphorylated on tyrosine via activation of the macrophage-colony-stimulating factor receptor TK. It is also tyrosine phosphorylated on Y225 as a consequence of leukemogenic protein TK (PTK) action. 8 THOC5 knockouts are embryonically lethal in the mouse, and we have shown that after induction of THOC5 knockdown, mice die from rapid hematopoietic failure due to primitive hematopoietic cell depletion. 9 This collapse is far swifter than observed with ATM-null mice, where self-renewal is compromised. 10 Thus in hematopoietic terms, we have a protein implicated in stem cell survival, which is a target for downstream action of receptor PTKs and leukemogenic PTKs and which modulates hematopoietic transcription factor action.
How these effects are achieved is not clear. Subcellular localization of THOC5 has been shown to be in a dynamic equilibrium with the protein shuttling between the cytosol and nucleus. 11 This raises the possibility that THOC5 protein could be critical in conveying survival/development signals, for example, from the macrophage-colony-stimulating factor receptor to the spliceosome/mRNA export complex. We have investigated pathways for THOC5 phosphorylation to determine its biological role. We report that THOC5 phosphorylation is sensitive to cellular oxidative status, an event mediated by Src PTK and CD45 protein tyrosine phosphatase and the stem cell chemokine CXCL12. The resultant phosphorylation governs mRNA binding and may modulate motility. We have elucidated a receptor-mediated activation of CD45/Src kinases/THOC5 phosphorylation that is affected by leukemogenic oncogenes and found to occur in leukemia stem cells.
MATERIALS AND METHODS

Cell lines
Ba/F3 cells were transfected with either MSCV retroviral vector or MSCV containing BCR/ABL, NPM/ALK, THOC5 and phosphomutants (Y to F) of NPM/ ALK and THOC5 as described previously.
12 K562 cells were maintained in RPMI (Gibco, Paisley, UK) with 10% (v/v) horse serum (Biowest, Nuaillé, France).
Patient samples
Human samples were leukapheresis products taken at the time of diagnosis from patients with chronic phase chronic myeloid leukemia (CML), with informed consent in accordance with the Declaration of Helsinki and approval of the National Health Service Greater Glasgow Institutional Review Board. The CD34 þ population was enriched using CliniMACS (Miltenyi Biotec, Bisley, UK) according to standard protocols, before storage as aliquots at À 150 1C. CML CD34 þ samples were cultured in serum-free media consisting of Iscove's modified Dulbecco's medium (Sigma-Aldrich Company Ltd, Gillingham, UK) supplemented with serum substitute (bovine serum albumin/insulin/transferrin, BIT9500; StemCell Technologies, Grenoble, France), 2 mM L-glutamine, 105 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM 2-mercaptoethanol and 0.8 mg/ ml low-density lipoprotein (Sigma-Aldrich). Serum-free medium was supplemented with a growth factor cocktail of 0.20 ng/ml recombinant human stem cell factor, 1 ng/ml recombinant human interleukin-6, 0.20 ng/ ml recombinant human granulocyte colony-stimulating factor, 0.05 ng/ml leukemia inhibitory factor, 0.2 ng/ml MIPa (macrophage inflammatory protein) (StemCell Technologies). Non-CML samples were CD34 þ -enriched leukapheresis products maintained and used as described for CML CD34 þ samples.
Preparation of cellular nuclei and western blotting
Nuclear proteins were enriched using a nuclear isolation kit from Active motif (la Hulpe, Belgium) with some modifications as described previously. 13 Western blotting was performed using standard protocols. Antibodies used were actin (Sigma-Aldrich; A5060), a-tubulin (Santa Cruz, Heidelberg, Germany; sc-5286), phospho-CRK-L (Cell Signalling  Technology 
Flow cytometry
For cell surface staining, CD34 þ cells were incubated with the appropriate antibodies for 20 min in the dark in 2% fetal calf serum/phosphatebuffered saline. Antibodies used were anti-CD34-APC, CD38-PerCP, CD90-PE (BD Biosciences, Oxford Science Park, Oxford, UK). For intracellular staining, CD34 þ and K562 cells were re-suspended in 'Fix and Perm' following the manufacturer's instructions (Merck Chemicals Ltd, Nottingham, UK). Primary antibody was added at room temperature for 1 h at 1/100 dilution and anti-rabbit FITC (Sigma-Aldrich) secondary for 30 min, and also at 1/100 dilution. Samples were analyzed by flow cytometry using the FACSCanto Flow Cytometer (Becton Dickinson, Oxford, UK). Data analysis was performed with FACSDiva (Becton Dickinson) and FlowJo (Tree Star, Olten, Switzerland) software. 20 Immunocytochemistry K562 cells and CML CD34 þ cells were left untreated or treated with the indicated drugs for 24 h. Cells were harvested and spotted onto glass microscope slides coated with poly-L-lysine and were subsequently fixed with 3.7% (w/v) formaldehyde for 15 min and permeablized using a 0.25% (w/v) Triton-phosphate-buffered saline solution for 20 min. Cells were blocked with 5% (w/v) bovine serum albumin-phosphate-buffered saline and stained with the indicated primary antibodies and appropriate secondary antibodies. Cells were concurrently stained with 4', 6-diamidino-2-phenylindole (Vectashield, Vector Laboratories Ltd, Peterborough, UK). Cells were imaged using a Zeiss Imager M1 AX10 fluorescence microscope (Carl Zeiss, Birmingham, UK) and subjected to deconvolution (AxioVision Software; Carl Zeiss) for image manipulation. Fluorescent signal was measured in three dimension by Image Processing and Analysis in Java (Image J) program.
Transient transfection
Transient transfection was achieved using the Amaxa Cell Line Nucleofector II device (Lonza, Verviers, Belgium) following the manufacturer's protocols optimized for Ba/F3 cells (Kit V and Program X-001, Lonza). Constructs used contained wild-type Src or viral (activated) Src. 21 Transfection efficiency was measured with the vector pmaxGFP. Cells were lysed 24 h post-electroporation and the phosphorylation of THOC5 assessed by western blot analysis.
Chemotaxis and cell motility assays
Chemotaxis assays were performed as described previously 22 using a Boyden chamber assay (Fisher Scientific, Loughborough, UK). The number of cells migrating through a 5 mm filter in response to 200 ng/ml CXCL12 was assessed over 6 h.
THOC5-mRNA complex isolation
Ba/F3 cells expressing NTAP-THOC5 and NTAP-THOC5 Y225F in MSCV were produced as described previously. 23 The THOC5-mRNA complexes were isolated and reverse transcription-polymerase chain reaction performed as described previously. 4 Briefly, cells were lysed in lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 0.4% NP-40) by freeze thawing and complexes isolated by incubation with streptavidin sepharose (GE Healthcare, Amersham, UK) in lysis buffer with 10 mM mercaptoethanol and 0.5 mM EDTA. Reverse transcription was carried out using oligo(dT) primers and the Omniscript reverse transcriptase kit from Qiagen (Crawley, UK). Primer pairs for Gigyf2 were 5 0 -CGCCGACTGGAAGAGAACC-3 0 and 5 0 -TTGCTGTGTTAGACTGCTGAC-3 0 (235 bp).
RESULTS
Structure function analysis on NPM/ALK reveals the key residues for activation of tyrosine phosphorylation
We have recently demonstrated that the THOC5 protein is a downstream target of the leukemogenic PTKs BCR/ABL, FIP1L/PDGFRa, TEL/PDGFR and NPM/ALK. 8 To discover the potential pathways lying downstream from the oncogenic PTKs, NPM/ALK mutants were expressed in Ba/F3 cells, and the effect of site-directed mutagenesis on the ability to promote phosphorylation on tyrosine 225 of THOC5 assessed. Mutation of NPM/ALK to create a kinase-dead version showed that the kinase activity of NPM/ALK is required for the observed increase in THOC5 phosphorylation (Figure 1a) .
Initial analysis of point-mutated NPM/ALK identified Y461F, Y567F and Y644F triple mutant as deficient in the ability to promote Y225 THOC5 phosphorylation (Figure 1a) . Single mutation analysis then identified Y567F, but not Y461F, Y644F NPM/ALK as deficient in this respect (Figure 1a) . The Y567 phosphoresidue of NPM/ALK is known to bind ShcA. 24 All three isoforms of the ShcA family are phosphorylated by PTKs, including p66 Shc, which can enhance reactive oxygen production by mitochondria.
Based on these data and the known ability of leukemogenic PTKs to stimulate reactive oxygen production, we assessed the ability of H 2 O 2 to promote THOC5 Y225 phosphorylation. Addition THOC5 is part of the THO complex that is critical for the processing and transport of RNA. Under normal conditions, THOC5 has a nuclear:cytoplasmic location and has been shown to shuttle between these compartments. We have previously shown THOC5 not only to be phosphorylated as a consequence of macrophagecolony-stimulating factor stimulation but also indeed to interact with its receptor c-fms. 11 We therefore hypothesized that the phosphorylation of THOC5 at Y225 was a cytosolic event. Western blot analysis of nuclear and cytosolic fractions showed phospho-Y225 to reside predominantly in the cytoplasm (Figure 1c) . We also generated an myc-tagged phosphomutant Y225F THOC5 to determine if phosphorylation influenced subcellular localization. This was not the case as the proportion of Y225F THOC5 in the nucleus was the same as native THOC5 (Figure 1d ).
As cellular stress can be caused by chemotherapeutic agents that can promote oxidative stress, 25 we also assessed the effects of etoposide on THOC5 phosphorylation. We have previously published that the appropriate concentration of etoposide to induce double-strand breaks in DNA (as a measure of biological response) in Ba/F3 cells is 20 mM.
26 Figure 2a demonstrates that treatment of cells with etoposide (20 mM) led to a transient increase in Y225 phosphorylation. THOC5 has been shown to be a target for the ATM kinase in respect of serine phosphorylation. ATM is a DNA damage-associated protein kinase as is the PTK c-ABL. To investigate the potential kinases that may be involved in the phosphorylation of THOC5, we undertook a study using protein kinase inhibitors implicated in downstream signaling from DNA damage. Figure 2b illustrates that while the inhibition of abl had no effect on Y225 phosphorylation, ATM inhibition increased THOC5 phosphorylation. Although one cannot discard the possibility, the differences are due to off-target effects. ATM inhibition has been shown to increase reactive oxygen species, 10 whereas Abl deficiency results in antioxidant gene overexpression, 27 which leads to opposite response to oxidative stress as compared with ATM. 28 This could account for the different consequences of their inhibition on THOC5 phosphorylation. With respect to kinases downstream of stress-induced signaling (etoposide or H 2 O 2 ), Src inhibitor completely abrogated THOC5 Y225 phosphorylation. Unexpectedly, MEK inhibition led to an increase in Y225 phosphorylation. Further studies treating the cells with the MEK and Src inhibitors, while simultaneously subjecting the cells to DNA damage by etoposide treatment, showed that Src activity is required for the etoposide-induced increase in THOC5 phosphorylation (Figure 2c ). The MEK inhibitor again resulted in an increase in phosphorylation. As already stated, we have previously shown that leukemogenic oncogenes lead to an increase in Y225 phosphorylation. As these oncogenes are known to activate Src, we asked the question whether inhibition of Src in oncogene-transfected cells would lead to a decrease in Y225 phosphorylation. This was indeed the case indicating that Y225 phosphorylation is downstream of Src following DNA damage and oncogene action (Figure 2d) . Furthermore, the induction of THOC5 Y225 phosphorylation following H 2 O 2 treatment was prevented when Src was inhibited (Figure 2e ). It has been reported that oxidative stress is linked to Src activation via lipid peroxidation. 29 As HNE is produced during oxidative stress, we asked whether HNE could lead to THOC5 Y225 phosphorylation and whether this was via Src activation. Treatment of cells with HNE led to an increase in phospho-Y225 (Figure 2f) , which was inhibited if Src inhibitors were present (Figure 2g ). Transient transfection of Ba/F3 cells with both active and inactive Src mutants further demonstrated that THOC5 Y225 is phosphorylated as a consequence of Src activity (Figure 2h) . Transfection of only the active Src led to an increase in Y225 phosphorylation.
THOC5 phosphorylation is elevated in primary CML stem cells Having established the fact that THOC5 Y225 was a target for numerous leukemogenic PTKs, we were keen to demonstrate that A role for THOC5 in response to oxidative stress F Griaud et al THOC5 phosphorylation was present in primary cells. To confirm we were seeing human leukemia-associated effects, we firstly confirmed that BCR/ABL led to an increase in THOC5 phosphorylation in a CML patient-derived cell line. K562 cells were treated with the BCR/ABL inhibitor dasatinib and then subjected to immunofluorescence microscopy using the phospho-Y225 THOC5 antibody (Figure 3a) : the loss of phospho-Y225 observed following dasatinib treatment was further confirmed by western blot (Figure 3b ) and phospho-CRKL assay demonstrated successful inhibition of BCR/ABL kinase activity. Flow cytometry measurements also demonstrated the sensitivity of phospho-Y225 levels to dasatinib treatment (Figure 3c) . These observations were then repeated in primary cells. First, we demonstrated by immunofluorescence ( Figure 4a ) and western blot (Figure 4b ) that phospho-Y225 levels were sensitive to dasatinib treatment in the bulk CD34 þ cell population from patients with CML. We then compared phospho-Y225 levels from CML and healthy individuals by flow cytometry not only in the bulk CD34 þ cell population but also in the more primitive CD34 þ CD38 À cells (Figure 4c ). All three cell populations showed higher levels of expression of phospho-Y225 THOC5 in CML than normal controls.
Dasatinib, in addition to inhibiting BCR/ABL, also inhibits Src. We were therefore interested whether the other two drugs commonly used in the treatment of CML, namely imatinib, and nilotinib, which have no Src inhibitory activity, also inhibited THOC5 Y225 phosphorylation. Figure 4d clearly shows that phospho-Y225 levels were reduced by all three drugs in all three cell populations. The potential role of THOC5 phosphorylation and its regulation by kinase inhibitors in primary leukemic stem cells led us to examine its function more closely. THOC5 Y225 involvement in stem cell homing chemokine signaling pathways There are a variety of cellular stimuli that can activate the Src kinase family. We therefore considered whether there were other hematopoietic stem cell-relevant pathways to THOC5 phosphorylation. CXCL12 is less able to promote chemotaxis in the presence of BCR/ABL. 30 This suggests some overlap in CXCL12 and BCR/ABL signaling in hematopoietic cells. As BCR/ABL induces THOC5 phosphorylation 8 and CXCL12 can promote activation of Src, we therefore investigated its effects on Y225 THOC5 phosphorylation. This would also demonstrate whether G-protein-coupled receptor agonists can affect THOC5 phosphorylation. We found that CXCL12 stimulation led to a transient increase in THOC5 phosphorylation (Figure 5a ). Further evidence that this was a direct consequence of CXCL12-mediated Src activation was obtained by investigating THOC5 phosphorylation status in CD45-null mast cells. In CD45 wild-type cells, Src was activated as illustrated by Src autophosphorylation on Y416, and THOC5 phosphorylated. In the absence of CD45, Src was not activated and THOC5 was not phosphorylated, indicating that Src and CD45 are upstream of THOC5 phosphorylation (Figure 5b ). We next investigated whether the phosphorylation of THOC5 had an effect on CXCL12-induced motility. Motility assays were performed on cells transfected with THOC5 and Y225F mutant THOC5. Figure 5c clearly shows that the presence of the Y-F mutation increases the cellular response to CXCL12. Thus, the data infer the Y225 site has a role in motile regulation via an as yet unidentified mechanism.
Phosphorylation of Y225 modulates mRNA binding We have previously identified mRNAs that bind to THOC5 and rely on THOC5 for export from the nucleus. 4 Here we tested whether mutation of tyrosine 225 had an effect on the ability of THOC5 to bind to just such an mRNA. THOC5 and THOC5 Y225F fused to streptavidin-inducing peptide (pNTAP) were expressed in Ba/F3 cells and the THOC5 containing messenger ribonucleoparticle enriched with streptavidin conjugated to sepharose. Western blot analysis of the cell lysates (input) and enriched samples (bound) demonstrate the isolation of THOC5-messenger ribonucleoparticle complex (Figure 5d, upper panels) . Reverse transcriptionpolymerase chain reaction analysis (Figure 5d , lower panels) clearly showed that mutation of Y225 abolishes THOC5's ability to bind to the mRNA for Gigyf2. This implicates the phosphorylation of tyrosine 225 of THOC5 via leukemogenic kinases in the modulation of mRNA export and hence translational control. Of note is the larger input of endogenous THOC5 in the lysate of THOC5 Y225F-expressing cells to ensure normalization of the two TAP-THOC constructs and subsequent co-enrichment of endogenous THOC5.
DISCUSSION
We have previously demonstrated that leukemogenic PTKs promote the phosphorylation of THOC5 on tyrosine 225 8 and that THOC5 is a key protein in the maintenance of hemopoietic stem cells in vivo. 9 The aims of this study were to Figure 3 . THOC5 Y225 phosphorylation is sensitive to dasatinib treatment in human CML cells. K562 cells were treated with 50 nM dasatinib for 24 h before THOC5 phospho-Y225 levels were assessed by immunofluorescence (a), western blot analysis (b) or flow cytometry (c). Western blot analysis of CRKL and phospho-CRKL were used as controls for the efficacy of dasatinib treatment and GAPDH as a loading control. Flow cytometry data are displayed as mean fluorescence intensity ± s.e.m.
A role for THOC5 in response to oxidative stress F Griaud et al identify the mechanism and consequences of THOC5 tyrosine phosphorylation.
Inferences from structure/function analysis of NPM/ALK implicated oxidative phosphorylation in the induction of THOC5 phosphorylation. Oxidative stress did indeed lead to an increase in THOC5 Y225 phosphorylation and we were able to further demonstrate that genotoxic stress increased THOC5 phosphorylation via oxidative stress including lipid peroxidation, and also activation of Src kinase (see Figure 6 ). Src family kinases such as Lyn have been shown to have a role in CML progression to blast crisis as well as being a direct source of imatinib and nilotinib resistance in CML, 31, 32 suggesting that THOC5 phosphorylation might be involved in the pathogenesis of leukemias. We showed that THOC5 tyrosine phosphorylation is higher in primary human CML CD34 þ cells than in normal cells and is expressed in the primitive CML CD34 þ CD38 À CD90 þ leukemia stem cells. While Abl inhibition had no effect on THOC5 phosphorylation in the non-transformed Ba/F3 cells that express c-Abl, this elevated THOC5 phosphorylation in primary CML cells was sensitive to Abl inhibitors when the active PTK BCR/ABL was present. The fact that imatinib and nilotinib are as effective as dasatinib (BCR/ABL and Src inhibitor) in reducing THOC5 phosphorylation suggests that BCR/ABL kinase inhibition may be sufficient to decrease THOC5 phosphorylation. Other leukemogenic PTKs enhance production of reactive oxygen species and this effect can be reversed by TK inhibitors. 33 Foxo3a can protect the CML stem cell via increased expression of antioxidative stress proteins. 34, 35 Nonetheless, there is a BCR/ABL-associated oxidative stress-related protein phosphorylation event seen in the CML stem cells, THOC5 phosphorylation.
Src activation has been shown to be regulated by CD45 tyrosine phosphatase, a key transmembrane glycoprotein involved in hematopoiesis and stem cell motility. 36 CD45 is able to dephosphorylate Src on either inhibitory tyrosine 527 or on the activating tyrosine 416, thus potentially having antagonistic action on different Src family kinase members and at different stages of development. 37 Using CD45-null/wild-type mast and Lin À cells, we have shown that CD45 phosphatase is required for Src activation (as determined by its autophosphorylation on tyrosine 416) and THOC5 phosphorylation on tyrosine 225. As CD45 also regulates motility, a process impaired in leukemia, we further investigated the connection between THOC5 and CD45 with stimulation of CD45 by CXCL12/CXCR4. CXCL12 is a chemokine expressed by the bone marrow stromal cells, which has a key role in the migration of hematopoietic stem/progenitor cells to bone marrow during fetal development and then their retention during adult life. 38, 39 Our data showed that THOC5 tyrosine phosphorylation is mediated by the CXCL12/CXCR4 pathway in such a way as to suggest that THOC5 phosphorylation participates in a negative feedback loop. CXCL12 leads to the phosphorylation of THOC5, whereas cells expressing the Y-F mutant of tyrosine 225 display an enhanced response to CXCL12. These observations are consistent with the fact that BCR/ABL induces THOC5 phosphorylation and display a reduced ability to respond to CXCL12. 23 It could be hypothesized that inhibition of CXCR4 with perixafor, for example, in the presence of CXCL12, would inhibit the phosphorylation of THOC5.
Our results are thus developing an understanding on THO complex modulation by TK oncogenes in leukemias and chemotactic factors that control stem cell retention in the marrow. This may, in part, be an explanation for the loss of stem cells so rapidly in THOC5-inducible knockout mice. 9 The CXCL12/CXCR4 pathway is perturbed in CML and has recently been reported to contribute to non-pharmacological drug resistance. 40 Indeed, it has been proposed that CXCR4 inhibition in conjunction with TK inhibition could over-ride drug resistance in CML and reduce residual disease. 41 We are currently assessing the role of THOC5 in motility and how this influences leukemic cell behavior. Preliminary proteomic data we have generated on the THOC5 interactome suggests that in addition to members of the THO complex, THOC5 interacts with numerous proteins involved in motility (T Tamura and AD Whetton, unpublished data). Thus, it may be a multifunctional protein.
THOC5 is required for primitive cell survival 9 and has been shown to modulate the specific nuclear export of mRNAs involved in cell development and hematopoiesis. 4 Given the role of reactive oxygen species in stem cell biology and THOC5 phosphorylation, we asked whether tyrosine 225 phosphorylation has any part in mRNA binding and export. Using a known THOC5 binding mRNA, we were able to demonstrate that indeed THOC5 phosphorylation on tyrosine 225 affected the mRNA binding properties of THOC5. Tyrosine 225 is actually within the mRNA binding domain of THOC5 (T Tamura, unpublished observations) and as we show that phosphorylation of this residue affects mRNA binding. Given that Y225 is a downstream target of numerous leukemogenic PTKs, it can be hypothesized that this phosphorylation event modulates mRNA processing and contributes to the pathogenesis of leukemia and as such offers a novel pathway for intervention in disease treatment.
In conclusion, we propose that THOC5 phosphorylation is part of a mechanism to inform the transcription/translation machinery of a change in environment requiring modulation of translation. Leukemogenic PTKs and receptors modulate the pathway by affecting THOC5 phosphorylation via reactive oxygen species production and Src TK activation (summary depicted in Figure 6 ). This in turn modulates THOC5 mRNA binding and expression of transcripts for key entities in transformation, such as Myc (T Tamura, unpublished observations). . Schematic summary of the results depicting the pathway from agonist to mRNA modulation. Agonists and oncogenes can induce changes in oxidative status within the cell and/or activate CD45 and/or Src. This leads to the phosphorylation of the THOC5 protein in a region known to bind mRNA. The mutation of Y225 to phenylalanine increases response to CXCL12, suggesting that the phosphorylation event is involved in a feedback loop to potentiate motile response. This may involve the mRNA binding function of THOC5 and translation. We propose THOC5 phosphorylation as a means of instructing the translational apparatus to change course or amplitude of activity due to altered cellular environment. This is affected by oncogenic PTKs with likely adverse consequences on a number of pathways via altered proteome.
